Mayne Pharma Group (AU:MYX)
ASX:MYX
Want to see AU:MYX full AI Analyst Report?
MYX Stock Chart & Stats
AU$6.01
-AU$0.13(-2.74%)
At close: 4:00 PM EST
AU$6.01
-AU$0.13(-2.74%)
Day’s Range― - ―
52-Week RangeAU$2.04 - AU$6.50
Previous CloseN/A
Volume149.18K
Average Volume (3M)593.75K
Market Cap
AU$182.80M
Enterprise ValueAU$172.26M
Total Cash (Recent Filing)AU$67.35M
Total Debt (Recent Filing)AU$44.62M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Aug 20, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding81,245,830
10 Day Avg. Volume776,050
30 Day Avg. Volume593,750
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.11
Price to Sales (P/S)1.01
P/FCF Ratio79.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Gross Margin And MixA near‑4ppt gross margin improvement reflects a durable shift toward higher‑margin products and better pricing/mix. Sustained higher gross margins increase cash generation potential and provide structural room to fund marketing, R&D or absorb pricing pressure over the next 2–6 months.
Dermatology Margin-led TurnaroundDermatology's marked margin expansion and branded mix increase indicates higher‑quality, more stable earnings. This segment now contributes disproportionate cashflow and resilience versus commoditised generics, supporting sustainable profit improvement and funding of strategic priorities.
Positive Operating Cash Flow And LiquidityPositive operating cash flow and a meaningful cash balance provide structural liquidity to execute strategic repositioning, invest in growth (NEXTSTELLIS promotion, Salisbury upgrade) and manage near‑term obligations without immediate refinancing, improving financial flexibility over coming quarters.
Bears Say
Negative Profitability MetricsDespite solid gross margins, persistent operating and net losses show the company struggles to translate revenue into sustainable profits. Negative margins constrain reinvestment, limit internal funding for growth initiatives and pressure return on equity until operating costs or mix improve materially.
Weak Free Cash Flow ConversionSeverely impaired free cash flow conversion signals recurring difficulties turning accounting earnings into cash. This structural weakness limits capital allocation optionality, raises sensitivity to cash outflows from investments or litigation, and increases reliance on external funding if trends persist.
Material One-off Charges And Litigation RiskLarge earn‑out adjustments and elevated legal/transaction expenses create ongoing earnings volatility and potential cash demands. Continued litigation and contingent payments can erode available cash, divert management focus and keep earnings volatile over the next several quarters.
Mayne Pharma Group News
MYX FAQ
What was Mayne Pharma Group’s price range in the past 12 months?
Mayne Pharma Group lowest share price was AU$2.04 and its highest was AU$6.50 in the past 12 months.
What is Mayne Pharma Group’s market cap?
Mayne Pharma Group’s market cap is AU$182.80M.
When is Mayne Pharma Group’s upcoming earnings report date?
Mayne Pharma Group’s upcoming earnings report date is Aug 20, 2026 which is in 76 days.
How were Mayne Pharma Group’s earnings last quarter?
Mayne Pharma Group released its earnings results on Feb 22, 2026. The company reported -AU$0.15 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.15.
Is Mayne Pharma Group overvalued?
According to Wall Street analysts Mayne Pharma Group’s price is currently Overvalued.
Does Mayne Pharma Group pay dividends?
Mayne Pharma Group pays a Notavailable dividend of AU$0.544 which represents an annual dividend yield of N/A. See more information on Mayne Pharma Group dividends here
What is Mayne Pharma Group’s EPS estimate?
Mayne Pharma Group’s EPS estimate is -0.3.
How many shares outstanding does Mayne Pharma Group have?
Mayne Pharma Group has 81,245,830 shares outstanding.
What happened to Mayne Pharma Group’s price movement after its last earnings report?
Mayne Pharma Group reported an EPS of -AU$0.15 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.783%.
Which hedge fund is a major shareholder of Mayne Pharma Group?
Currently, no hedge funds are holding shares in AU:MYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mayne Pharma Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.78%
12-Months-Change
Fundamentals
Return on Equity
-23.02%
Trailing 12-Months
Asset Growth
-10.41%
Trailing 12-Months
Company Description
Mayne Pharma Group
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
MYX Company Deck
MYX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally constructive picture: the underlying business remained cash generative with improved gross margins, higher total direct contribution, strong Dermatology profitability and clear momentum across multiple Women's Health products. These positives are tempered by an 8% decline in underlying EBITDA, significant one‑off noncash earn‑out and litigation/transaction charges, elevated near‑term legal and earn‑out cash outflows, ANNOVERA returns issues and an investment phase in International that compressed contribution. Management framed many negatives as discrete or investment‑led and emphasized strategic repositioning, operational improvements and capital allocation optionality.View all AU:MYX earnings summariesTechnical Analysis
Starpharma Holdings Limited
―
Vita Life Sciences Limited
―
Medical Developments International Limited
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---